Log In
Print
BCIQ
Print
Print this Print this
 

ch14.18 (APN311)

  Manage Alerts
Collapse Summary General Information
Company Apeiron Biologics AG
DescriptionChimeric mAb against GD2
Molecular Target GD2
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase III
Standard IndicationNeuroendocrine tumors
Indication DetailsTreat neuroblastoma
Regulatory Designation

Partner

Endo International plc; Medison Pharma Ltd.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today